



Novel Melatonin Based Therapies

Guest Editors:

Prof. Dr. Alejandro Romero Martínez

Sección Departamental de Farmacología y Toxicología, Facultad de Veterinaria, Universidad Complutense de Madrid, Avda. Puerta de Hierro s/n, 28040-Madrid, Spain
manarome@ucm.es

Prof. Dr. Russel J. Reiter

Department of Cellular & Structural Biology, The UT Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA
REITER@UTHSCSA.EDU

Prof. Dr. Germaine Escames

Health Sciences Technology Park, Universidad de Granada, Granada, Spain
gescames@ugr.es

Deadline for manuscript submissions:

closed (30 September 2021)

Message from the Guest Editors

Dear Colleagues,

Melatonin has emerged in the last decade as a promising agent to counteract most of the physiopathological events that trigger several disorders. Most of the beneficial molecular functions exerted by melatonin are due to the following: Its small size and amphiphilic nature allow the molecule to easily diffuse through any membrane, reaching cytosolic, mitochondrial and nuclear compartments. It is a potent scavenger of free radicals, both directly and indirectly, inhibiting the activity of prooxidative enzymes and stimulating antioxidant enzymes through interactions with two high-affinity G protein-coupled receptors.

In this Special Issue, we will focus on the use of melatonin as an adjuvant treatment in a wide variety of diseases, which could be of critical importance for the development of novel therapeutic strategies.

This Special Issue will serve as a forum to bring together researchers of different fields to share advances in the knowledge of the therapeutic uses of melatonin.

Prof. Dr. Alejandro Romero Martínez
Prof. Dr. Russel J. Reiter
Guest Editors

